Author:
Innocenti Federico,Ramírez Jacqueline,Obel Jennifer,Xiong Julia,Mirkov Snezana,Chiu Yi-Lin,Katz David A.,Carr Robert A.,Zhang Wei,Das Soma,Adjei Araba,Moyer Ann M.,Chen Pei Xian,Krivoshik Andrew,Medina Diane,Gordon Gary B.,Ratain Mark J.,Sahelijo Leonardo,Weinshilboum Richard M.,Fleming Gini F.,Bhathena Anahita
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Genetics (clinical),Genetics,Molecular Biology,Molecular Medicine,General Pharmacology, Toxicology and Pharmaceutics
Reference34 articles.
1. Drug development and clinical trials - the path to an approved cancer drug.;Rubin;Nat Rev Clin Oncol,2012
2. Pharmacokinetic variability of anticancer agents.;Undevia;Nat Rev Cancer,2005
3. Mechanism of action of E7010, an orally active sulfonamide antitumor agent: inhibition of mitosis by binding to the colchicine site of tubulin.;Yoshimatsu;Cancer Res,1997
4. Phase I study of E7010.;Yamamoto;Cancer Chemother Pharmacol,1998
5. .Phase 1 study of ABT-751, a novel microtubule inhibitor, in patients with refractory hematologic malignancies.;Yee;Clin Cancer Res,2005
Cited by
13 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献